Curated News
By: NewsRamp Editorial Staff
August 11, 2025
Oragenics Advances Breakthrough Concussion Treatment with Intranasal Delivery Tech
TLDR
- Oragenics advances ONP-002, aiming to be the first FDA-approved concussion treatment, offering investors a unique opportunity in the growing nasal drug delivery market projected to exceed $40 billion by 2030.
- Oragenics secured HREC approval in Australia, appointed Southern Star Research as CRO, and finalized a cGMP agreement with Sterling Pharma Solutions, setting the stage for Phase IIa trials in Q3 2025.
- Oragenics' intranasal delivery technology promises a breakthrough in neurological care, potentially improving recovery for concussion patients and paving the way for treatments in neurodegenerative diseases.
- Discover how Oragenics' innovative intranasal delivery platform could revolutionize treatment for concussions and beyond, targeting the brain directly to minimize side effects and enhance efficacy.
Impact - Why it Matters
This news is pivotal as it highlights a potential breakthrough in treating concussions and other neurological conditions, offering hope for millions affected worldwide. Oragenics' innovative approach could significantly reduce recovery times and improve outcomes, marking a major advancement in neurological care. The implications extend beyond concussions, with potential applications in treating a range of brain-related conditions, underscoring the transformative potential of this technology in healthcare.
Summary
Oragenics (NYSE American: OGEN), a pioneering biotechnology firm, is making significant strides with its innovative intranasal delivery technology aimed at treating neurological conditions. The company has announced key strategic and financial achievements for Q2 2025, including the approval from the Human Research Ethics Committee in Australia, the appointment of Southern Star Research as its Clinical Research Organization (CRO), and a cGMP manufacturing agreement with Sterling Pharma Solutions in the U.S. These milestones are critical as Oragenics advances ONP-002, its lead candidate, towards becoming the first FDA-approved pharmacological treatment for concussion. With Phase IIa trials slated to begin in Q3 2025, the company's technology promises rapid, targeted drug delivery to the brain, minimizing side effects and offering potential applications in treating acute neurological emergencies and chronic neurodegenerative diseases. The global nasal drug delivery market, where Oragenics is positioning itself as a leader, is expected to surpass $40 billion by 2030.
For more details, the full press release can be accessed here. Oragenics is not just developing treatments; it's spearheading a movement towards brain-first recovery, aiming to transform the approach to neurological trauma for patients, clinicians, and healthcare systems worldwide.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Advances Breakthrough Concussion Treatment with Intranasal Delivery Tech
